PARP1 and cancer: Furthermore, BRCA defective cancer cells are sensitive to PARP inhibition (Antolin et al., 2020; Jannetti et al., 2020; Rose et al., 2020), and this synthetic lethality suggests that PARP and BRCA1/2 function in different pathways.